ClinicalTrials.gg

Program

gilteritinib

Also written as “Gilteritinib”, “ASP2215” and “gilteritinib mini tablet”.

Its studies are mostly in Leukemia, Myeloid, Acute · Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Furthest: phase 3, since Apr 16, 201520 company-led studies, 2 open or runningNext primary completion: Jul 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma182 open or runningphase 3since Apr 16, 2015Nov 6, 2013Jul 31, 2028phase 2 · NCT05520567
AbbVie10 open or runningphase 1since Aug 8, 2018Aug 8, 2018none ahead
Bristol-Myers Squibb10 open or runningphase 1since Mar 26, 2020Mar 26, 2020none ahead

Also a collaborator on its studies: Hoffmann-La Roche.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Nov 6, 2013.

  1. Sep 25, 2015Phase 2 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT02561455 · 9 enrolled · United States
  2. Oct 7, 2015Phase 1 study in Hepatic ImpairmentAstellas Pharma · NCT02571816 · 24 enrolled · United States
  3. Apr 22, 2016Phase 3 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT02752035 · 183 enrolled · United States, Australia, Belgium and more
  4. Oct 5, 2016Phase 2 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT02927262 · 98 enrolled · United States, Brazil, Canada and more
  5. Dec 1, 2016Phase 3 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT02997202 · 356 enrolled · United States, Australia, Belgium and more
  6. Jun 8, 2017Phase 3 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT03182244 · 276 enrolled · China, Malaysia, Russia and more
  7. Aug 8, 2018AbbVie's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to AbbVieAbbVie · NCT03625505 · 61 enrolled · United States
  8. Nov 1, 2018Phase 2 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT03730012 · 11 enrolled · United States
  9. May 20, 2019Phase 1 study in Healthy VolunteerAstellas Pharma · NCT03964038 · 48 enrolled · United States
  10. Jan 21, 2020Phase 2 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT04240002 · 9 enrolled · United States, Germany, Italy and more
  11. Mar 26, 2020Bristol-Myers Squibb's first study: phase 1 study in Leukemia, Myeloid, AcuteNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT04336982 · 22 enrolled · United States, Belgium, Canada and more
  12. Jan 6, 2021Phase 1 study in Renal ImpairedAstellas Pharma · NCT04699877 · 17 enrolled · United States, Bulgaria
  13. Aug 26, 2022Phase 2 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT05520567 · 70 enrolled · United States
  14. Aug 5, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungAstellas Pharma · NCT07140016 · 40 planned · United States, France, Spain

Ahead

  1. Jul 31, 2028Primary completion: phase 2 study in Leukemia, Myeloid, AcuteAstellas Pharma · NCT05520567
  2. Dec 31, 2029Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungAstellas Pharma · NCT07140016

TargetBeta

“An orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), ”NCIt, by rule
“Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Tyrosine-protein kinase receptor UFO inhibitor”ChEMBL 37, by rule

Studies

All 20 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07140016Carcinoma, Non-Small-Cell Lung · United States, France, Spain1RecruitingAstellas PharmaDec 31, 202940
NCT05520567Leukemia, Myeloid, Acute · United States2Active, not recruitingAstellas PharmaJul 31, 202870
NCT04699877Renal Impaired · United States, Bulgaria1CompletedAstellas PharmaJul 18, 202217
NCT04336982Leukemia, Myeloid, Acute · United States, Belgium, Canada and more1TerminatedBristol-Myers SquibbOct 25, 202322
NCT04240002Leukemia, Myeloid, Acute · United States, Germany, Italy and more2TerminatedAstellas PharmaMar 11, 20259
NCT03964038Healthy Volunteer · United States1CompletedAstellas PharmaJul 2, 201948
NCT03730012Leukemia, Myeloid, Acute · United States2CompletedAstellas PharmaMay 14, 202111
NCT03625505Leukemia, Myeloid, Acute · United States1CompletedAbbVieAug 31, 202161
NCT03182244Leukemia, Myeloid, Acute · China, Malaysia, Russia and more3CompletedAstellas PharmaDec 25, 2023276
NCT02997202Leukemia, Myeloid, Acute · United States, Australia, Belgium and more3CompletedAstellas PharmaJan 7, 2023356
NCT02927262Leukemia, Myeloid, Acute · United States, Brazil, Canada and more2CompletedAstellas PharmaMay 25, 202198
NCT02752035Leukemia, Myeloid, Acute · United States, Australia, Belgium and more3CompletedAstellas PharmaMar 10, 2023183
NCT02571816Hepatic Impairment · United States1CompletedAstellas PharmaMar 5, 201624
NCT02561455Leukemia, Myeloid, Acute · United States2CompletedAstellas PharmaJul 28, 20209
NCT02456883Advanced Solid Tumors · United States1CompletedAstellas PharmaMay 20, 20176
NCT02421939Leukemia, Myeloid, Acute · United States, Belgium, Canada and more3CompletedAstellas PharmaSep 17, 2018371
NCT02310321Leukemia, Myeloid, Acute · Japan, South Korea, Taiwan2CompletedAstellas PharmaAug 25, 202197
NCT02236013Leukemia, Myeloid, Acute · United States1CompletedAstellas PharmaJul 26, 202180
NCT02181660Leukemia, Myeloid, Acute · Japan1CompletedAstellas PharmaJun 27, 201624
NCT02014558Leukemia, Myeloid, Acute · United States, Germany, Italy2CompletedAstellas PharmaAug 4, 2017265

How it is read

Names in the registry

  • “Gilteritinib”, 11 entries
  • “gilteritinib”, 7 entries
  • “ASP2215”, 1 entry
  • “gilteritinib mini tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.